Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10871792 | FEBS Letters | 2011 | 8 Pages |
Abstract
⺠Neuroprotective and regenerative treatments may improve long-term outcomes in multiple sclerosis. ⺠Restricting demyelination and improving repair may reduce axonal transection. ⺠Pathways promoting oligodendrocyte viability and myelination include gp130 cytokines, neurotrophins, IGFs and RXR signaling. ⺠Inhibitors of maturation and myelin formation include bone morphogenetic proteins and the canonical Wnt and Notch pathways. ⺠Although these avenues are promising, no therapies are yet approved that target these areas in multiple sclerosis patients.
Related Topics
Life Sciences
Agricultural and Biological Sciences
Plant Science
Authors
Jingya Zhang, Elisabeth G. Kramer, Linnea Asp, Dipankar J. Dutta, Kristina Navrazhina, Trinh Pham, John N. Mariani, Azeb Tadesse Argaw, Carmen V. Melendez-Vasquez, Gareth R. John,